Guney Kenan, Ozbilim Gulay, Derin Alper Tunga, Cetin Safiye
Department of Ear Nose Throat Head and Neck Surgery, Akdeniz University Medical Faculty, Antalya, Turkey.
Auris Nasus Larynx. 2007 Dec;34(4):481-6. doi: 10.1016/j.anl.2007.03.014. Epub 2007 May 1.
PTEN (phosphatase and tensin homologue deleted on chromosome 10), also referred to as MMAC1 (mutated in multiple advanced cancers) gene was recently identified as a putative tumor suppressor in a variety of malignant tumors. PTEN expression has been investigated in some squamous cell carcinomas (SCC) of head and neck. However, there is only little knowledge about laryngeal malignancies. Therefore, we examined PTEN product protein immunohistochemically in 30 consecutive laryngeal specimens from patients with laryngeal SCC and compared the results according to the clinicopathologic characteristics of the patients.
Surgical resection specimens of patients with laryngeal SCC were stained for PTEN protein using a primary rabbit polyclonal anti-PTEN antibody. Standard avidin-biotin immunohistochemical analysis was used to process the sections. The extent and intensity of PTEN staining in the specimens were compared according to the age and sex of the patients and localization, differentiation, size and stage of the tumor.
Out of 30 tumoral specimens (23 glottic and 7 supraglottic) 22 showed decreased PTEN staining intensity compared to the adjacent normal tissue. The extent of cytoplasmic PTEN staining was significantly less in supraglottic tumors (p < 0.05). When characteristics of the patients were analyzed according to the extent of cytoplasmic PTEN staining no difference was observed according to age, sex, measure, differentiation, T or N status.
A significant decrease in the extent of PTEN staining was observed in supraglottic SCC. It could be worthwhile to test if PTEN expression is diminished in patients with more aggressive laryngeal tumors, with special attention to tumor localization in larger series.
PTEN（第10号染色体缺失的磷酸酶及张力蛋白同源物），也被称为MMAC1（在多种晚期癌症中发生突变）基因，最近被确定为多种恶性肿瘤中的一种假定肿瘤抑制基因。PTEN的表达已在一些头颈部鳞状细胞癌（SCC）中进行了研究。然而，关于喉恶性肿瘤的了解却很少。因此我们对30例喉鳞状细胞癌患者的连续喉标本进行了PTEN产物蛋白的免疫组织化学检查，并根据患者的临床病理特征比较了结果。
使用兔抗PTEN多克隆一抗对喉鳞状细胞癌患者的手术切除标本进行PTEN蛋白染色。采用标准抗生物素蛋白-生物素免疫组织化学分析方法处理切片。根据患者的年龄、性别以及肿瘤的定位、分化程度、大小和分期，比较标本中PTEN染色的范围和强度。
在30个肿瘤标本（23个声门型和7个声门上型）中，与相邻正常组织相比，22个标本的PTEN染色强度降低。声门上型肿瘤中细胞质PTEN染色范围明显较小（p < 0.05）。根据细胞质PTEN染色范围分析患者特征时，未观察到年龄、性别、尺寸、分化程度、T或N状态方面的差异。
在声门上型鳞状细胞癌中观察到PTEN染色范围显著降低。对于更具侵袭性的喉肿瘤患者，检测PTEN表达是否降低可能是有价值的，在更大规模的研究中需特别关注肿瘤定位。
